BRI3

BRI3 is a brain-enriched transmembrane protein that acts as an endogenous negative regulator of amyloid precursor protein (APP) processing and amyloid-β (Aβ) production (PMID:19366692). It binds APP directly and colocalizes with it along neurites, and its overexpression reduces both α- and β-cleavage of APP while knockdown increases Aβ secretion, consistent with BRI3 limiting secretase access to APP; unlike BRI2, it binds the β-cleaved APP C-terminal fragment poorly and is a weak γ-cleavage inhibitor (PMID:19366692). BRI3 additionally engages the β-secretase machinery through a physical interaction with the cytosolic tail of BACE1, and is itself proteolytically matured by the convertase furin into a secreted C-terminal fragment (PMID:15606899). A second, complementary anti-amyloidogenic activity resides in its BRICHOS domain, which binds Aβ40/Aβ42 and inhibits Aβ42 fibril formation in vitro, functioning as a molecular chaperone that more efficiently suppresses non-fibrillar aggregation but less efficiently blocks fibril formation than the related BRI2 BRICHOS domain (PMID:30480246, PMID:32555390). BRI3 abundance is controlled post-translationally by an NRBP1-based Cullin-RING ligase (Cul2/Cul4A) that targets it for proteasomal degradation, such that NRBP1 depletion stabilizes BRI3 and lowers Aβ (PMID:32160551), and its expression is driven transcriptionally by Wnt/β-catenin/TCF4 signaling (PMID:20538055). Beyond amyloid biology, BRI3 binds and is dephosphorylated by protein phosphatase 1 (PMID:26515131), stabilizes the microtubule network and attenuates NGF-induced neurite outgrowth through association with the microtubule-destabilizing protein SCG10 (PMID:18452648), and is required for TNF-α-induced lysosomal cell death (PMID:14592447).

1. 2003 Medium

   Established the first cellular function for BRI3, linking it specifically to death receptor signaling rather than general apoptosis.

   Evidence Antisense knockdown of BRI3 in L929 cells with TNF cell-death assay and lysosomal localization by fractionation/imaging

   PMID:14592447

   Open questions at the time

   • No molecular effector linking BRI3 to the lysosomal death pathway identified
   • Pathway specificity tested in a single cell line
2. 2005 High

   Connected BRI3 to the amyloidogenic machinery by identifying BACE1 as a partner and defining how BRI3 itself is processed.

   Evidence Yeast two-hybrid against BACE1 cytosolic tail, reciprocal Co-IP, colocalization, and furin/PC7/PC5A processing assays

   PMID:15606899

   Open questions at the time

   • Functional consequence of BRI3-BACE1 binding on β-secretase activity not resolved
   • Role of the secreted ~4-kDa fragment unknown
3. 2008 Medium

   Revealed a cytoskeletal role by showing BRI3 sequesters SCG10 to stabilize microtubules and restrain neurite outgrowth.

   Evidence Yeast two-hybrid, GST pull-down, Co-IP, in vitro microtubule turbidimetry, and PC12 neurite outgrowth assay

   PMID:18452648

   Open questions at the time

   • In vivo relevance to neuronal development not established
   • Single lab without independent confirmation
4. 2009 High

   Defined BRI3's central role as a direct APP binder and endogenous brake on Aβ production, distinguishing it mechanistically from BRI2.

   Evidence Reciprocal Co-IP from mouse brain, colocalization in N2a neurites, RNAi with Aβ ELISA and APP fragment analysis

   PMID:19366692

   Open questions at the time

   • Structural basis for blocking secretase access not determined
   • Whether inhibition is steric or allosteric unresolved
5. 2010 Medium

   Placed BRI3 expression under Wnt/β-catenin/TCF4 control, providing a transcriptional input to its abundance.

   Evidence SAGE/microarray, promoter TCF-element analysis, ChIP, luciferase reporter, and lithium treatment in Huh7 cells

   PMID:20538055

   Open questions at the time

   • Demonstrated in hepatocellular carcinoma cells, not neurons
   • Link between Wnt-driven BRI3 levels and Aβ regulation not tested
6. 2015 Medium

   Identified PP1 as a phosphatase that binds and dephosphorylates BRI3, implying its activity is phosphoregulated.

   Evidence In silico motif prediction, in vitro binding, in vivo Co-IP, PP1-motif mutagenesis, confocal colocalization

   PMID:26515131

   Open questions at the time

   • Functional consequence of BRI3 phosphorylation state unknown
   • Kinase acting on BRI3 not identified
7. 2020 High

   Demonstrated dual mechanisms governing BRI3's anti-amyloid action: post-translational degradation control and an intrinsic chaperone domain.

   Evidence Co-IP/MS of the NRBP1-Cul2/Cul4A CRL with knockdown and Aβ quantification; recombinant BRICHOS biophysics with in vitro fibril and aggregation assays

   PMID:32160551 PMID:32555390

   Open questions at the time

   • Whether NRBP1-mediated degradation of BRI3 occurs in vivo brain not shown
   • Physiological relevance of distinct BRI3 vs BRI2 BRICHOS chaperone activities unclear

• How BRI3's diverse activities — APP/BACE1 binding, BRICHOS chaperone function, SCG10/microtubule regulation, PP1 dephosphorylation, and TNF-induced lysosomal death — are integrated within a single protein and coordinated in vivo remains unresolved.
• No structural model of BRI3 or its complexes
• Physiological role in vivo and in neurodegeneration not established by loss-of-function organismal studies
• IFITM3/MGAT1 interactions lack functional follow-up